Neumora Therapeutics, Inc. Common Stock
NASDAQ:NMRABiotechnology
-$0.10 today
- Market cap
- $69.21M
- Beta
- 2.76
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$1.24
Volume 1.50M
Average 2.02M
NMRA Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Neumora Therapeutics, Inc. Common StockNASDAQ: NMRA
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin declines year over year
Q1 FY2026 selling, general & admin of $14.27M fell 24.1% year over year, behind the -17.1% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 3.3% from the prior quarter. Over 3 fiscal years it compounded at +24.5% a year.
Context
- Selling, general & admin increased in 2 of the last 3 fiscal years.
What to watch
Whether selling, general & admin reaches the consensus estimate from 9 analysts of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the -3.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $14.27M+3.3% QoQ
- Last fiscal yearDec 2025
- $60.09M-3.9% YoY
- LTMMar 2026
- $55.57M-17.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -24.1% | -100.0% | -75.9 pp |
| 1 year | -3.9% | -100.0% | -96.1 pp |
| 3-year CAGR | +24.5% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 60.09M USD
- Year-over-year change
- -3.9%
- 4-year CAGR
- +25.1%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 60.09M | -3.9% |
| FY2024 | 2024-12-31 | 62.54M | +39.6% |
| FY2023 | 2023-12-31 | 44.81M | +44.0% |
| FY2022 | 2022-12-31 | 31.12M | +26.8% |
| FY2021 | 2021-12-31 | 24.55M | — |
Selling, General & Admin vs competitors
How NMRA compares with its peers on the latest reported figures
- NMRA's LTM Mar 2026 selling, general & admin of $55.57M is the 5th highest of the 10 companies compared; the peer median is $54.46M.
- Its year-over-year change of -17.1% is the 7th highest of 10, against a peer median of -5.9%.
- Over three fiscal years its annual growth of +24.5% compares with a peer median of +14.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $142.24M | +17.3% | +60.5% | 153.6% | |
| LTM Mar 2026 | $82.03M | +32.5% | — | 103.6% | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $77.08M | +17.2% | +94.2% | 1041.9% |
| LTM Mar 2026 | $76.67M | +0.6% | +17.4% | 120.8% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $55.57M | -17.1% | +24.5% | — |
| LTM Mar 2026 | $54.46M | -19.1% | +6.0% | 94.0% | |
| LTM Mar 2026 | $47.81M | -5.9% | +14.2% | 54.2% | |
| LTM Mar 2026 | $34.94M | -61.3% | — | 50.2% | |
| LTM Mar 2026 | $33.4M | -31.3% | -6.4% | 337.6% | |
| LTM Mar 2026 | $29.77M | -10.8% | -11.7% | — | |
| Peer median (excluding NMRA) | $54.46M | -5.9% | +14.2% | 112.2% | |
Competitors are the stored peer set for NMRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 668K | 0 | 5M |
| Gross Profit | 0 | 0 | (668K) | 0 | (5M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 212.78M | 104.75M | 142.72M | 200.93M | 176.07M |
| Selling, General & Admin | 24.55M | 31.12M | 44.81M | 62.54M | 60.09M |
| Operating Expenses | 237.32M | 135.87M | 187.53M | 263.46M | 236.16M |
| Depreciation & Amortization | 538K | 594K | 668K | 631K | 208K |
| EBITDA | (236.77M) | (130.31M) | (234.99M) | (242.98M) | (233.37M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (237.32M) | (135.87M) | (188.19M) | (263.46M) | (241.16M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 4.56M | 16.61M | 19.93M | 8.34M |
| Interest Expense | 0 | 0 | 0 | 0 | 3.22M |
| Other Income / Expenses | 11K | 4.97M | (47.46M) | 19.86M | 4.36M |
| Income Before Tax | (237.31M) | (130.9M) | (235.66M) | (243.61M) | (236.8M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 268K | 178K | 130K |
| Net Income | (237.31M) | (130.9M) | (235.93M) | (243.79M) | (236.93M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.56) | (0.86) | (1.49) | (1.53) | (1.45) |
| EPS (Diluted) | (1.56) | (0.86) | (1.49) | (1.53) | (1.45) |
| Weighted Avg Shares | 151.95M | 151.95M | 158.83M | 159.38M | 163.39M |
| Weighted Avg Shares (Diluted) | 151.95M | 151.95M | 158.83M | 159.38M | 163.39M |
Neumora Therapeutics, Inc. Common Stock
NASDAQ:NMRA
Intrinsic Alpha fair value
Locked
Current Price
$0.37
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.